SOTIO Strengthens Management Team with Appointment of Robyn Hunter as Chief Financial Officer
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announces the appointment of Robyn Hunter as chief financial officer. Ms. Hunter is an accomplished CFO who brings an extensive array of financial experience to SOTIO, including her extensive knowledge of biotech and capital markets. She joins SOTIO to oversee the long-term financing strategy.
SOTIO Doses First Patient in AURELIO-04 Phase 2 Trial of SOT101 in Combination with KEYTRUDA® (pembrolizumab)
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that the first patient was dosed in its Phase 2, AURELIO-04 combination trial of SOT101, an IL-15 superagonist and MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy KEYTRUDA® (pembrolizumab), in patients with selected advanced/refractory solid tumors.
Data from SOTIO’s Phase 1/1b AURELIO-03 Trial of SOT101 Demonstrate Clinical Benefit in Patients with Solid Tumors
SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announces updated interim safety and efficacy data from its Phase 1/1b AURELIO-03 dose escalation study of the IL-2/IL-15 receptor βγ superagonist, SOT101, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors. Data from the study show that SOT101 has a favorable safety profile. The recommended Phase 2 dose was defined at 12 µg/kg SOT101.